Acquisition will add C3i's multilingual service-desk support to Telerx's call centers
Telerx (Horsham, PA), which has been growing its voice and online capabilities for life sciences and consumer packaged goods (CPG) since the 1980s, will acquire C3i (Morristown, NJ) in a transaction expected to close by the end of this quarter. The combination can be looked on two ways: enabling Telerx to expand its range of customer interaction services to a global market through C3i’s global footprint; and as a way to add C3i services, such as training on hardware platforms, help-desk and similar support for pharma sales teams, to the Telerx customer base. C3i is, for example, one of the solution partners of Veeva, the Pleasanton, CA, company whose cloud-based customer relationship-management platform is a popular option among pharma companies.
Linda Schellenger, Telerx president, tells Pharmaceutical Commerce that the company’s core functions are providing healthcare professionals and patients reimbursement support, adherence programs, and drug safety (pharmacovigilance). Last year, it acquired Sentrx, one of the leading outsourced providers of adverse-event reporting. Most of Telerx’s business is with life sciences companies (it is a subisidiary of Merck), but has a substantial business in CPG as well. Through that CPG expertise, it expects to bring more sophisticated multichannel marketing capabilities to pharma. “CPG is ahead of life sciences in using the full range of multichannel tools, such as voice, text and social media,” she says, noting that regulatory constraints on pharma is keeping its involvement limited. “But it will be opening up as regulations become clear, and we’ll have a leg up when it does."
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.